Trials / Completed
CompletedNCT00748852
Safety Study of JTT-302 in Subjects With Low HDL-C Levels
An Eight Week, Open-label Extension Study Evaluating the Safety of JTT-302 Administered Once Daily in Subjects With Low HDL-C Levels Who Have Completed the Treatment Phase of Study AT302-U-06-003
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Akros Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid parameters and CETP activity and mass.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JTT-302 | JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2008-09-09
- Last updated
- 2013-02-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00748852. Inclusion in this directory is not an endorsement.